Viatris Inc. (VTRS)
USD 7.52
(3.51%)
USD 7.52
(3.51%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.96 Billion USD | 17.17% |
| 2022 | 4.84 Billion USD | -7.08% |
| 2021 | 5.21 Billion USD | 35.08% |
| 2020 | 3.85 Billion USD | 3.45% |
| 2019 | 3.72 Billion USD | 1.7% |
| 2018 | 3.66 Billion USD | 3.6% |
| 2017 | 3.53 Billion USD | -17.68% |
| 2016 | 4.29 Billion USD | 47.17% |
| 2015 | 2.92 Billion USD | 26.09% |
| 2014 | 2.31 Billion USD | 17.16% |
| 2013 | 1.97 Billion USD | 17.37% |
| 2012 | 1.68 Billion USD | 16.01% |
| 2011 | 1.45 Billion USD | 7.54% |
| 2010 | 1.35 Billion USD | 3.4% |
| 2009 | 1.3 Billion USD | -4.71% |
| 2008 | 1.37 Billion USD | 72.59% |
| 2007 | 794.21 Million USD | 0.0% |
| 2006 | 340.22 Million USD | 5.87% |
| 2005 | 306.89 Million USD | -5.41% |
| 2004 | 324.45 Million USD | 7.29% |
| 2003 | 302.42 Million USD | 0.0% |
| 2002 | 228.76 Million USD | -36.91% |
| 2001 | 362.59 Million USD | 50.41% |
| 2000 | 241.07 Million USD | 12.81% |
| 1999 | 213.7 Million USD | 29.75% |
| 1998 | 164.7 Million USD | 17.81% |
| 1997 | 139.8 Million USD | 28.85% |
| 1996 | 108.5 Million USD | 7.11% |
| 1995 | 101.3 Million USD | 23.54% |
| 1994 | 82 Million USD | 48.28% |
| 1993 | 55.3 Million USD | 35.54% |
| 1992 | 40.8 Million USD | 98.06% |
| 1991 | 20.6 Million USD | 4.57% |
| 1990 | 19.7 Million USD | 16.57% |
| 1989 | 16.9 Million USD | 5.63% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.21 Billion USD | -32.7% |
| 2024 Q2 | 1.73 Billion USD | 42.38% |
| 2023 Q2 | 1.24 Billion USD | 8.62% |
| 2023 Q3 | 1.26 Billion USD | 1.98% |
| 2023 Q4 | 1.8 Billion USD | 43.01% |
| 2023 Q1 | 1.14 Billion USD | -36.25% |
| 2023 FY | 4.51 Billion USD | -6.75% |
| 2022 Q4 | 1.79 Billion USD | 39.69% |
| 2022 FY | 4.84 Billion USD | -8.31% |
| 2022 Q3 | 1.28 Billion USD | 5.3% |
| 2022 Q2 | 1.21 Billion USD | 8.05% |
| 2022 Q1 | 1.12 Billion USD | -42.03% |
| 2021 Q4 | 1.94 Billion USD | 15.46% |
| 2021 Q2 | 2.03 Billion USD | -4.47% |
| 2021 Q3 | 1.68 Billion USD | -17.15% |
| 2021 FY | 5.28 Billion USD | 35.4% |
| 2021 Q1 | 2.12 Billion USD | 4.53% |
| 2020 Q4 | 2.03 Billion USD | 123.89% |
| 2020 Q1 | 843.2 Million USD | -20.03% |
| 2020 Q2 | 996.4 Million USD | 18.17% |
| 2020 Q3 | 908.8 Million USD | -8.79% |
| 2020 FY | 3.89 Billion USD | 21.73% |
| 2019 FY | 3.2 Billion USD | 1.84% |
| 2019 Q3 | 833.7 Million USD | -19.64% |
| 2019 Q4 | 1.05 Billion USD | 26.47% |
| 2019 Q1 | 910.8 Million USD | -11.29% |
| 2019 Q2 | 1.03 Billion USD | 13.91% |
| 2018 Q4 | 1.02 Billion USD | 22.94% |
| 2018 Q1 | 843.2 Million USD | -13.7% |
| 2018 FY | 3.14 Billion USD | -6.36% |
| 2018 Q2 | 931.4 Million USD | 10.46% |
| 2018 Q3 | 835.1 Million USD | -10.34% |
| 2017 Q2 | 771 Million USD | -12.7% |
| 2017 Q1 | 883.2 Million USD | -28.37% |
| 2017 FY | 3.35 Billion USD | 1.09% |
| 2017 Q3 | 894.7 Million USD | 16.04% |
| 2017 Q4 | 977.1 Million USD | 9.21% |
| 2016 Q2 | 784.6 Million USD | -6.05% |
| 2016 Q3 | 1.5 Billion USD | 91.21% |
| 2016 Q4 | 1.23 Billion USD | -17.81% |
| 2016 FY | 3.32 Billion USD | 16.49% |
| 2016 Q1 | 835.1 Million USD | 15.78% |
| 2015 Q3 | 744.2 Million USD | -2.69% |
| 2015 Q1 | 691.1 Million USD | 9.14% |
| 2015 FY | 2.85 Billion USD | 34.08% |
| 2015 Q4 | 721.3 Million USD | -3.08% |
| 2015 Q2 | 764.8 Million USD | 10.66% |
| 2014 Q3 | 546.5 Million USD | -10.47% |
| 2014 Q2 | 610.4 Million USD | 15.89% |
| 2014 Q1 | 526.7 Million USD | -6.53% |
| 2014 Q4 | 633.19 Million USD | 15.86% |
| 2014 FY | 2.12 Billion USD | 10.84% |
| 2013 Q3 | 478.3 Million USD | 0.0% |
| 2013 Q1 | 477.85 Million USD | -0.6% |
| 2013 Q4 | 563.5 Million USD | 17.81% |
| 2013 FY | 1.91 Billion USD | 6.51% |
| 2013 Q2 | 426.82 Million USD | -10.68% |
| 2012 FY | 1.8 Billion USD | 19.39% |
| 2012 Q4 | 480.71 Million USD | 6.67% |
| 2012 Q3 | 450.66 Million USD | -0.64% |
| 2012 Q2 | 453.57 Million USD | 8.58% |
| 2012 Q1 | 417.72 Million USD | 10.77% |
| 2011 Q1 | 355.3 Million USD | -4.55% |
| 2011 FY | 1.5 Billion USD | 10.27% |
| 2011 Q2 | 386.71 Million USD | 8.84% |
| 2011 Q4 | 377.1 Million USD | -3.37% |
| 2011 Q3 | 390.23 Million USD | 0.91% |
| 2010 Q4 | 372.25 Million USD | 8.13% |
| 2010 Q1 | 317.05 Million USD | -7.23% |
| 2010 Q2 | 335.16 Million USD | 5.71% |
| 2010 Q3 | 344.27 Million USD | 2.72% |
| 2010 FY | 1.36 Billion USD | 3.27% |
| 2009 Q3 | 329.42 Million USD | -6.86% |
| 2009 Q4 | 341.78 Million USD | 3.75% |
| 2009 Q1 | 298.39 Million USD | 817.79% |
| 2009 FY | 1.32 Billion USD | -4.46% |
| 2009 Q2 | 353.68 Million USD | 18.53% |
| 2008 Q4 | -41.57 Million USD | -111.87% |
| 2008 Q3 | 350.3 Million USD | 2.97% |
| 2008 Q1 | 721.75 Million USD | 0.0% |
| 2008 Q2 | 340.21 Million USD | -52.86% |
| 2008 FY | 1.38 Billion USD | 415.52% |
| 2007 Q3 | 129.74 Million USD | 19.43% |
| 2007 Q4 | - USD | -100.0% |
| 2007 FY | 269.11 Million USD | -20.9% |
| 2007 Q1 | 95.64 Million USD | 133.96% |
| 2007 Q2 | 108.63 Million USD | 13.59% |
| 2006 Q2 | 71.05 Million USD | 3.04% |
| 2006 FY | 340.22 Million USD | 5.87% |
| 2006 Q1 | 68.95 Million USD | -11.32% |
| 2006 Q3 | 61.54 Million USD | -13.38% |
| 2006 Q4 | 40.87 Million USD | -33.58% |
| 2005 Q2 | 108.38 Million USD | 8.37% |
| 2005 Q1 | 100.01 Million USD | 15.81% |
| 2005 FY | 321.36 Million USD | 20.06% |
| 2005 Q4 | 77.75 Million USD | -8.78% |
| 2005 Q3 | 85.24 Million USD | -21.35% |
| 2004 Q2 | 53.25 Million USD | -23.84% |
| 2004 Q3 | 81.73 Million USD | 53.47% |
| 2004 Q4 | 86.36 Million USD | 5.67% |
| 2004 FY | 267.66 Million USD | 3.97% |
| 2004 Q1 | 69.92 Million USD | -5.11% |
| 2003 Q2 | 50.51 Million USD | -33.43% |
| 2003 Q1 | 75.87 Million USD | 13.45% |
| 2003 Q4 | 73.69 Million USD | 0.22% |
| 2003 FY | 257.44 Million USD | 12.54% |
| 2003 Q3 | 73.53 Million USD | 45.57% |
| 2002 FY | 228.76 Million USD | -36.91% |
| 2002 Q4 | 66.88 Million USD | 8.34% |
| 2002 Q3 | 61.73 Million USD | 16.59% |
| 2002 Q2 | 52.95 Million USD | 7.46% |
| 2002 Q1 | 49.27 Million USD | -14.19% |
| 2001 Q4 | 57.42 Million USD | -11.02% |
| 2001 Q2 | 57.52 Million USD | -64.96% |
| 2001 Q1 | 164.16 Million USD | 143.63% |
| 2001 FY | 362.59 Million USD | 50.41% |
| 2001 Q3 | 64.53 Million USD | 12.2% |
| 2000 Q1 | 60.87 Million USD | -1.82% |
| 2000 Q4 | 67.38 Million USD | 3.06% |
| 2000 Q3 | 65.38 Million USD | -0.34% |
| 2000 Q2 | 65.6 Million USD | 7.77% |
| 2000 FY | 241.07 Million USD | 12.81% |
| 1999 FY | 213.7 Million USD | 29.75% |
| 1999 Q1 | 65.6 Million USD | 16.93% |
| 1999 Q2 | 58.6 Million USD | -10.67% |
| 1999 Q3 | 59.6 Million USD | 1.71% |
| 1999 Q4 | 62 Million USD | 4.03% |
| 1998 Q2 | 44.6 Million USD | 0.22% |
| 1998 FY | 164.7 Million USD | 17.81% |
| 1998 Q3 | 47.5 Million USD | 6.5% |
| 1998 Q4 | 56.1 Million USD | 18.11% |
| 1998 Q1 | 44.5 Million USD | 28.61% |
| 1997 Q1 | 34 Million USD | -3.68% |
| 1997 FY | 139.8 Million USD | 28.85% |
| 1997 Q4 | 34.6 Million USD | -29.39% |
| 1997 Q3 | 49 Million USD | 34.25% |
| 1997 Q2 | 36.5 Million USD | 7.35% |
| 1996 FY | 108.5 Million USD | 7.11% |
| 1996 Q2 | 36 Million USD | 27.66% |
| 1996 Q4 | 35.3 Million USD | 2.62% |
| 1996 Q3 | 34.4 Million USD | -4.44% |
| 1996 Q1 | 28.2 Million USD | -4.08% |
| 1995 Q1 | 26.6 Million USD | 1.92% |
| 1995 FY | 101.3 Million USD | 23.54% |
| 1995 Q2 | 25.7 Million USD | -3.38% |
| 1995 Q4 | 29.4 Million USD | 16.21% |
| 1995 Q3 | 25.3 Million USD | -1.56% |
| 1994 Q4 | 26.1 Million USD | 5.24% |
| 1994 Q1 | 20.6 Million USD | -13.45% |
| 1994 Q3 | 24.8 Million USD | 4.64% |
| 1994 Q2 | 23.7 Million USD | 15.05% |
| 1994 FY | 82 Million USD | 48.28% |
| 1993 Q3 | 19.1 Million USD | 3.24% |
| 1993 Q4 | 23.8 Million USD | 24.61% |
| 1993 FY | 55.3 Million USD | 35.54% |
| 1993 Q1 | 14.6 Million USD | -13.61% |
| 1993 Q2 | 18.5 Million USD | 26.71% |
| 1992 Q3 | 13.6 Million USD | 16.24% |
| 1992 Q1 | 11.1 Million USD | -4.31% |
| 1992 FY | 40.8 Million USD | 98.06% |
| 1992 Q2 | 11.7 Million USD | 5.41% |
| 1992 Q4 | 16.9 Million USD | 24.26% |
| 1991 Q3 | 6.4 Million USD | 14.29% |
| 1991 Q1 | 3.9 Million USD | -30.36% |
| 1991 Q4 | 11.6 Million USD | 81.25% |
| 1991 FY | 20.6 Million USD | 4.57% |
| 1991 Q2 | 5.6 Million USD | 43.59% |
| 1990 Q2 | 5.6 Million USD | 21.74% |
| 1990 FY | 19.7 Million USD | 16.57% |
| 1990 Q4 | 5.6 Million USD | 1.82% |
| 1990 Q1 | 4.6 Million USD | -11.54% |
| 1990 Q3 | 5.5 Million USD | -1.79% |
| 1989 Q2 | 5 Million USD | 107.5% |
| 1989 FY | 16.9 Million USD | 5.63% |
| 1989 Q1 | -66.7 Million USD | 0.0% |
| 1989 Q4 | 5.2 Million USD | 6.12% |
| 1989 Q3 | 4.9 Million USD | -2.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -72191.198% |
| Alpha Teknova, Inc. | 45.85 Million USD | -12909.66% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -2944.193% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -13201.155% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -3647.362% |
| Cosmos Health Inc. | 26.18 Million USD | -22688.086% |
| Journey Medical Corporation | 54.59 Million USD | -10828.124% |
| Embecta Corp. | 528.4 Million USD | -1029.088% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -2094.25% |
| Dynavax Technologies Corporation | 219.14 Million USD | -2622.444% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | -911.193% |
| Pacira BioSciences, Inc. | 326.37 Million USD | -1727.978% |
| PainReform Ltd. | 9.58 Million USD | -62150.626% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -45357.836% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -45357.836% |
| SCYNEXIS, Inc. | 51.84 Million USD | -11406.905% |
| Safety Shot Inc | 12.1 Million USD | -49167.141% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -194286.919% |
| Procaps Group, S.A. | 199.47 Million USD | -2890.871% |
| Theratechnologies Inc. | 72.75 Million USD | -8100.148% |
| Harrow Health, Inc. | 89.97 Million USD | -6530.989% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -63060.068% |
| Biofrontera Inc. | 39.95 Million USD | -14830.554% |
| DURECT Corporation | 43.71 Million USD | -13547.718% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -1027.784% |
| Cronos Group Inc. | 96.7 Million USD | -6069.126% |
| OptiNose, Inc. | 85.1 Million USD | -6910.529% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -2470.221% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -15137.913% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 62500.377% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -1799.221% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -61211.292% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -13761.577% |
| Radius Health, Inc. | 265.92 Million USD | -2143.494% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -43001.717% |
| ProPhase Labs, Inc. | 37.85 Million USD | -15661.651% |
| Phibro Animal Health Corporation | 260.29 Million USD | -2192.027% |
| Procaps Group S.A. | 187.24 Million USD | -3086.253% |
| Alvotech | 285.43 Million USD | -1990.156% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -60623.664% |
| Rockwell Medical, Inc. | 15.37 Million USD | -38706.426% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -9870.087% |
| SIGA Technologies, Inc. | 22.04 Million USD | -26965.707% |
| Tilray Brands, Inc. | 251.35 Million USD | -2273.556% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -12066.279% |
| Shineco, Inc. | 17.94 Million USD | -33140.957% |
| PetIQ, Inc. | 192.72 Million USD | -2995.654% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -149383.681% |
| Incannex Healthcare Limited | 30.05 Million USD | -19751.928% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -273.699% |
| Alimera Sciences, Inc. | 62.64 Million USD | -9424.273% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -782347.554% |
| Assertio Holdings, Inc. | 368.58 Million USD | -1518.65% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -101268.244% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -33401.358% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -28083.192% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -28253.165% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -3516.563% |
| Hempacco Co., Inc. | 7.59 Million USD | -78438.012% |
| Talphera, Inc. | 11.99 Million USD | -49642.371% |
| Alvotech | 285.43 Million USD | -1990.156% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -4139.877% |
| Lantheus Holdings, Inc. | 344.9 Million USD | -1629.801% |
| Currenc Group, Inc. | 24 Million USD | -24756.586% |
| Kamada Ltd. | 45.42 Million USD | -13033.668% |
| Indivior PLC | 911 Million USD | -554.896% |
| Evoke Pharma, Inc. | 12.4 Million USD | -47976.326% |
| Flora Growth Corp. | 10.57 Million USD | -56295.69% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -28253.165% |
| Evolus, Inc. | 189.75 Million USD | -3044.041% |
| HUTCHMED (China) Limited | 436.23 Million USD | -1267.647% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -3770.723% |
| Akanda Corp. | 3.48 Million USD | -171167.01% |